相似文献
1
White biotechnology: ready to partner and invest in.
Biotechnol J. 2006 Jul-Aug;1(7-8):787-94. doi: 10.1002/biot.200600087.
2
Korean biotechs seize opportunity to list on public markets.
Nat Biotechnol. 2005 Oct;23(10):1189-90. doi: 10.1038/nbt1005-1189.
3
Public markets show signs of life.
Nat Biotechnol. 2003 Aug;21(8):833-4. doi: 10.1038/nbt0803-833.
4
Could bank loans solve Europe's biotech financing slump?
Nat Biotechnol. 2005 Dec;23(12):1459-60. doi: 10.1038/nbt1205-1459.
5
The responsibilities of growing up.
Nat Biotechnol. 2006 Mar;24(3):225. doi: 10.1038/nbt0306-225.
6
European markets target foreign biotechs.
Nat Biotechnol. 2003 Jul;21(7):719. doi: 10.1038/nbt0703-719.
7
The stampede to convertibles.
Nat Biotechnol. 2003 Aug;21(8):855. doi: 10.1038/nbt0803-855.
8
Lack of private financing hobbles emerging biotech regions.
Nat Biotechnol. 2006 Jan;24(1):7-9. doi: 10.1038/nbt0106-7.
9
Sustaining agbiotechnology through lean times.
Nat Biotechnol. 2003 Sep;21(9):996-1002. doi: 10.1038/nbt0903-996.
10
Looking at US versus European exit opportunities.
Nat Biotechnol. 2005 Oct;23(10):1203.
Zotero 插件